Benzodiazepine compositions for treating epidermal hyperplasia and related disorders
View Patent ↗The present invention provides, for example, pharmaceutical compositions comprising a benzodiazepine compound and an agent selected from the group consisting of a topical steroid, a keratolytic agent, a topical retinoid, a coal tar, and a vitamin D-3 analog. The pharmaceutical compositions are useful for treating medical disorders, such as epidermal hyperplasia.
1. A pharmaceutical composition comprising:
a) a benzodiazepine compound of formula I that regulates epidermal hyperplasia; and
b) an agent selected from the group consisting of a topical corticosteroid, a keratolytic agent, a topical retinoid, a coal tar, and a vitamin D-3 analog;
wherein said benzodiazepine compound of formula I is represented by:
including pharmaceutically acceptable salts thereof; wherein
R 1 is one of the following:
2. The pharmaceutical composition of claim 1 , wherein said benzodiazepine compound is Bz-423.
3. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is used to treat an epidermal hyperplasia.
4. The pharmaceutical composition of claim 3 , wherein said epidermal hyperplasia is caused by psoriasis.
5. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is formulated for oral administration, parenteral administration, topical administration, or nasal administration.
6. The pharmaceutical composition of claim 1 , wherein said agent is a topical corticosteroid selected from the group consisting of triamcinolone acetonide and betamethasone dipropionate.
7. The pharmaceutical composition of claim 1 , wherein said agent is calcipotriene.
8. The pharmaceutical composition of claim 1 , wherein said agent is a topical retinoid selected from the group consisting of tretinoin and tazarotene.
9. The pharmaceutical composition of claim 1 , wherein R 1 is one of the following:
10. The pharmaceutical composition of claim 2 , wherein said agent is a topical corticosteroid selected from the group consisting of triamcinolone acetonide and betamethasone dipropionate.
11. The pharmaceutical composition of claim 1 , wherein said benzodiazepine compound has the formula:
12. The pharmaceutical composition of claim 1 , wherein the concentration of the benzodiazepine compound is less than 10 μM.